Leukotriene B 4 antagonism ameliorates experimental lymphedema
نویسندگان
چکیده
منابع مشابه
Leukotriene B4 antagonism ameliorates experimental lymphedema.
Acquired lymphedema is a cancer sequela and a global health problem currently lacking pharmacologic therapy. We have previously demonstrated that ketoprofen, an anti-inflammatory agent with dual 5-lipoxygenase and cyclooxygenase inhibitory properties, effectively reverses histopathology in experimental lymphedema. We show that the therapeutic benefit of ketoprofen is specifically attributable t...
متن کاملCysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm
Cysteinyl-leukotrienes (cys-LTs) are 5-lipoxygenase-derived lipid mediators involved in the pathogenesis and progression of inflammatory disorders, in particular asthma. We have previously found evidence linking these mediators to increased levels of proteolytic enzymes in tissue specimens of human abdominal aortic aneurysm (AAA). Here we show that antagonism of the CysLT1 receptor by monteluka...
متن کامل630 Leukotriene B
H u m a n polymorphonuclear leukocytes (PMN) 1 metabolize arachidonic acid via the lipoxygenase pa thway to a number of monoand di-hydroxyeicosatetraenoic acids (HETE) (1-7). These H E T E include 5-D-HETE, 12-L-HETE, 12-L-hydroperoxyETE, and at least four isomers of 5,12-diHETE. In addit ion to arachidonic acid, these H E T E have been shown to induce chemotaxis (8-11), chemokinesis (12, 13), ...
متن کاملAntagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.
Activation of hepatic stellate cells in response to chronic inflammation represents a crucial step in the development of liver fibrosis. However, the molecules involved in the interaction between immune cells and stellate cells remain obscure. Herein, we identify the chemokine CCL5 (also known as RANTES), which is induced in murine and human liver after injury, as a central mediator of this int...
متن کاملLeukotriene B4 receptor antagonism reduces monocytic foam cells in mice.
Leukotriene B4 (LTB4) is a potent chemotactic agent that activates monocytes through the LTB4 receptor (BLTR). We tested the hypothesis that LTB4 receptor blockade would slow atherosclerotic progression by inhibiting monocyte recruitment. Homozygous low-density receptor knockout (LDLr(-/-)) mice and apolipoprotein E deficient (apoE(-/-)) mice were treated with a specific LTB4 receptor antagonis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Science Translational Medicine
سال: 2017
ISSN: 1946-6234,1946-6242
DOI: 10.1126/scitranslmed.aal3920